Upregulation of embryonic stem cell marker Nanog in human gingival fibroblasts stimulated with cyclosporine A: An in vitro study

Cheng-Chia Yu a,b†, Ni-Yu Su b,c†, Chia-Ming Liu b, Li-Chiu Yang c, Chung-Hung Tsai d, Yu-Chao Chang b,c*  

a Institute of Oral Sciences, Chung Shan Medical University, Taichung, Taiwan  
b Department of Dentistry, Chung Shan Medical University Hospital, Taichung, Taiwan  
c School of Dentistry, Chung Shan Medical University, Taichung, Taiwan  
d Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan

Received 31 August 2016; Final revision received 14 November 2016  
Available online 24 December 2016

KEYWORDS  
cyclosporine A; embryonic stem cell marker; gingival overgrowth; Nanog

Abstract  
Background/purpose: Gingival overgrowth is a common side effect of medication with the immunosuppressant cyclosporine A (CsA). This study proposed to verify whether Nanog, an embryonic stem cell marker, contributes to gingival overgrowth stimulated with CsA in human gingival fibroblasts (HGFs).

Materials and methods: The effect of CsA on HGFs was used to elucidate whether Nanog expression could be induced by CsA using quantitative real-time reverse transcription-polymerase chain reaction and Western blotting. Cell growth in CsA-treated HGFs with Nanog lentivirus-mediated short hairpin RNA interference knockdown was evaluated by tetrazolium bromide reduction assay.

Results: CsA upregulated Nanog transcript in HGFs in a dose-dependent manner (P < 0.05). CsA was also shown to increase Nanog protein expression in HGFs in a dose-dependent manner (P < 0.05). In addition, downregulation of Nanog by lentiviral infection significantly inhibited CsA-stimulated cell growth in HGFs (P < 0.05).

Conclusion: CsA upregulated Nanog expression and cell growth in HGFs, while silencing Nanog effectively reversed these phenomena. Nanog may act as a major switch in the pathogenesis of CsA-induced gingival overgrowth.

© 2017 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Cyclosporine A (CsA) is an immunosuppressant widely used to avoid allograft rejection and treat several immune-related conditions. Unfortunately, gingival overgrowth is one of the significant adverse effects of medication with CsA,1 with a quoted prevalence of between 8% and 100% in transplant patients.2 The pathogenesis of CsA-induced gingival overgrowth is still not entirely understood. It is believed that the imbalance of extracellular matrix (ECM) molecules accumulation may contribute to CsA-induced gingival overgrowth.3–9 Recently, the upregulation of epithelial–mesenchymal transition (EMT) makers Snail10 and Slug11 were also found to play an important role in the pathogenesis of CsA-induced gingival overgrowth.

The pluripotency-associated transcription factor Nanog was identified based on its ability to support embryonic stem cell (ESC) self-renewal,12 and is involved in the maintenance of the undifferentiated state of pluripotent stem cells.13 Recently, ESC marker Nanog was found in keloid scar,14 and liver fibrosis derived from alcohol-related hepatocellular carcinoma.15 However, it is unclear whether Nanog is involved in the pathogenesis of CsA-induced gingival overgrowth.

In this study, the effect of CsA on normal human gingival fibroblasts (HGFs) was used to elucidate the possible role of Nanog in the pathogenesis of CsA-induced gingival overgrowth. Quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) and Western blotting were used to determine the effects of CsA on the expression of Nanog in HGFs. In addition, cell growth in CsA-treated HGFs with Nanog lentivirus-mediated short hairpin RNA interference (shRNAi) knockdown was evaluated by tetrazolium bromide reduction assay.

Materials and methods

Cell culture

After approval by the Institutional Review Board at Chung Shan Medical University Hospital, Taichung, Taiwan, normal gingival tissue samples were obtained from three healthy male individuals (mean age, 26.7 years; range, 20–32 years) undergoing routine surgical crown lengthening, with little if any evidence of inflammation and no systemic medication. HGFs were cultured by using an explant technique as described previously.3,9

Nanog expression analysis

HGFs were arrested in G0 by serum deprivation according to our previous experiments.4,7 Nearly confluent monolayers of HGFs were washed with serum-free medium and immediately thereafter exposed at the indicated incubation times to 0 ng/mL, 100 ng/mL, 500 ng/mL, and 1000 ng/mL CsA (Sigma–Aldrich, St. Louis, MO, USA). Cell lysates were collected at 24 hours for qRT-PCR and western blot assays. Cultures without fetal calf serum (Gibco BRL, Gaithersburg, MD, USA) were used as negative controls.

qRT-PCR

Total RNA of cells was purified using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) as described previously.10,11 Nanog primers were designed: (forward) ATTCAGGACGCTCTGTTCTTC and (reverse) TTTTTTGGAGACTCTTCTTCGTC. The GAPDH housekeeping gene was amplified as a reference standard. GAPDH primers were designed: (forward) CATCCTCGCTCTACTG and (reverse) GCCGTGCCTACCACTTC.

Western blotting

The extraction of proteins from cells and immunoblotting procedure were performed as described previously.9,9

Nanog knockdown in CsA-treated HGFs by lentivirus-mediated short hairpin RNA interference

The pLV-RNai vector was purchased from Biosettia (San Diego, CA, USA). The method of cloning the double-stranded shRNA has been described previously.10,11 Lentiviral vectors expressing shRNA that targets human Nanog (sh-Nanog-1: 5’-AAAAGCATCGACTTGTAAGATTGGATCCCAAATTCTTTACAGTCGGATGC-3’; sh-Nanog-2: 5’-AAAAGCTTGTGTACCTGTAATTTGGATCCAAATTCTTTACAGTCGGATGC-3’) were synthesized and cloned into pLVNai to generate a lentiviral expression vector. shRNA that targets luciferase (sh-Luc: 5’-CCGGACTTACCGTGAGTACTCAGTAAGTGGATCCAAATTCTTTACAGTCGGATGC-3’) was utilized for an experimental control.

Cell growth

HGFs were placed in 96-well plates, washed with phosphate-buffered saline, and cultured without fetal calf serum for starvation overnight. After treatment with 500 ng/mL CsA for 24 hours, cell growth was tested using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay kit (Sigma–Aldrich) as described previously.10,11

Statistical analysis

Three replicates of each experiment were performed in each test. All assays were repeated three times to ensure reproducibility. Statistical analysis was carried out by one-way analysis of variance. Tests of differences of the treatments were analyzed by Duncan’s test and a value of P < 0.05 was considered statistically significant.

Results

To examine the effect of CsA on Nanog expression, HGFs were treated with CsA and the levels of transcript and protein were measured by qRT-PCR and Western blotting, respectively. CsA increased Nanog transcription in HGFs in a dose-dependent manner (P < 0.05; Figure 1). CsA also upregulated Nanog protein expression in a dose-dependent manner (P < 0.05). From the Alphamager 2000 (Alpha Innotech Corp., San Leandro, CA, USA), the amount of
Nanog was elevated about 1.9-, 3.8-, and 3.1-fold at concentrations of 100 ng/mL, 500 ng/mL, and 1000 ng/mL CsA, respectively, as compared with the controls (Figure 2).

Downregulation of Nanog in CsA-treated HGFs was achieved by viral transduction with lentiviral vector expressing shRNA targeting Nanog. In addition, lentiviral vector expressing sh-Luc was used as a control. qRT-PCR confirmed that lentivirus expressing both sh-Nanog markedly reduced the expression level of CsA-induced Nanog expression in HGFs (Figure 3). Western blot confirmed that knockdown of Nanog reduced Nanog expression in CsA-stimulated HGFs (Figure 4). The quantitative measurement of Nanog protein expression by the AlphaImager 2000 is shown in the lower panel of Figure 4.

In addition, knockdown of Nanog inhibited CsA-stimulated cell growth in HGFs (Figure 5). These results suggested that Nanog expression acts as a major switch in the pathogenesis of CsA-induced gingival overgrowth.

**Discussion**

The pathogenesis of CsA-induced gingival overgrowth is not entirely understood. Nanog constitutes the core transcriptional network of pluripotency and has shown to reprogram human somatic fibroblasts into ESC-like pluripotent cells, termed inducible pluripotent stem cells. Recently, Nanog was found to induce hyperplasia without initiating tumors in tet-Nanog mice. In this study, to the best of our knowledge, CsA was first found to upregulate Nanog mRNA and protein expression in HGFs. In addition, qRT-PCR and Western blotting confirmed that lentivirus expressing both

**Figure 1** Nanog mRNA expression was examined by quantitative real-time reverse transcription-polymerase chain reaction. Human gingival fibroblasts were exposed for 24 hours in medium containing various concentrations of cyclosporine A as indicated. The relative Nanog mRNA expression represents the mean ± standard deviation. * Represents significant difference from control values with P < 0.05.

**Figure 2** Nanog protein expression was examined by western blotting. Human gingival fibroblasts were treated with indicated concentration of CsA for 24 hours. β-Actin was used as protein loading control (Upper panel). Levels of Nanog protein treated with CsA were measured by AlphaImager 2000. The relative level of Nanog protein expression for each sample was normalized against β-actin signal, and the control was set as 1.0. Triplicate experiments were performed. * Represents significant difference from control values with P < 0.05 (Lower panel). CsA = cyclosporine A.

**Figure 3** The silencing effect of Nanog short hairpin RNA in CsA-treated HGFs was validated transcriptionally by quantitative real-time reverse transcription-polymerase chain reaction. Single cell suspension of HGFs was transduced with sh-Luc or sh-Nanog lentivirus, individually or concurrently, and treated with or without CsA (500 ng/mL) as indicated. The relative Nanog mRNA expression represents the mean ± standard deviation. * P < 0.05, Sh-Luc + CsA group versus control group. ** P < 0.05, Sh-Nanog-1 + CsA or Sh-Nanog-2 + CsA versus Sh-Luc + CsA group. CsA = cyclosporine A; HGF = human gingival fibroblast.

sh-Nanog-1 and sh-Nanog-2 significantly inhibited the levels of CsA-induced Nanog transcription and protein expression in HGFs. Taken together, these results suggest that CsA contributes to the pathogenesis of gingival overgrowth via the augmentation of Nanog expression in HGFs. In addition,
the time-dependent effect may be also an important issue for CsA-induced gingival overgrowth, and it merits further study.

EMT, a transdifferentiation program that converts epithelial state into mesenchymal state, is critical for development and disease including drug-induced gingival overgrowth. Researchers have shown that EMT can promote and maintain stemness properties of stem cells. Recently, we reported that the upregulation of Snail and Slug may play an important role in the pathogenesis of CsA-induced gingival overgrowth. Thus, the detailed molecular mechanisms involved in the regulatory links between Nanog and EMT properties are worthy of further investigation.

CsA-induced gingival overgrowth consists of several cell types, with fibroblasts being one of the most predominant cells. The aberrant expression of Nanog has been linked to increased cell growth and proliferation in pancreatic cancer cells and human dental pulp cells. In this study, knockdown of Nanog suppressed CsA-stimulated cell growth in HGFs. Our results provide new avenues for the design of novel antifibrotic therapies for CsA-induced gingival overgrowth through targeting Nanog.

As far as we know, this is the first attempt to evaluate the role of Nanog expression in HGFs stimulated with CsA. CsA upregulated Nanog expression and cell growth in HGFs, while silencing Nanog reversed these phenomena. Nanog may play an important role in the pathogenesis of CsA-induced gingival overgrowth. Therefore, the design of novel antifibrotic therapies for CsA-induced gingival overgrowth through targeting Nanog may be considered. We aim to verify these current in vitro data in a future in vivo study on clinical samples of gingival overgrowth from patients receiving CsA. In addition to Nanog, other ESC markers such as Oct4, SSEA-4, and Sox2 will be investigated in the future to verify the possible roles of ESCs in CsA-induced gingival overgrowth.

Conflict of interest

The authors have no conflicts of interest relevant to this article.

Acknowledgments

The work was supported by the National Science Council, Taiwan (NSC 101-2314-B-040-012).

References

1. Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and
2. Wright G, Welbury RR, Hosey MT. Cyclosporin-induced gingival overgrowth in children. *Int J Paediatr Dent* 2005;15:403–11.
3. Lin HJ, Tsai CH, Huang FM, Chang YC. The upregulation of type I plasminogen activator inhibitor in human gingival fibroblasts stimulated with cyclosporin A. *J Periodont Res* 2007;42:39–44.
4. Tsai CH, Chang TY, Chang YC. Upregulation of lysyl oxidase expression in cyclosporin A-induced gingival overgrowth. *J Dent Sci* 2009;4:13–7.
5. Tsai CH, Yang SF, Huang FM, Chang YC. The upregulation of cystatin C in human gingival fibroblasts stimulated with cyclosporin A. *J Periodont Res* 2009;44:459–64.
6. Ho YC, Lin HJ, Tsai CH, Chang YC. Regulation of type I plasminogen activator inhibitor in human gingival fibroblasts with cyclosporine A. *Oral Dis* 2010;16:396–401.
7. Chang TY, Tsai CH, Chang YC. The upregulation of heat shock protein 47 in human gingival fibroblasts stimulated with cyclosporin A. *J Periodont Res* 2010;45:317–22.
8. Lee SS, Tsai CH, Kuan YH, Huang FM, Chang YC. The upregulation of transglutaminase-2 by cyclosporine A in human gingival fibroblasts is augmented by oxidative stress. *J Periodontol* 2013;84:1469–75.
9. Tsai CH, Lee SS, Huang FM, Yu CC, Yang SF, Chang YC. The modulation of hypoxia-inducible factor-1α/plasminogen activator inhibitor-1 axis in human gingival fibroblasts stimulated with cyclosporine A. *J Formos Med Assoc* 2015;114:58–63.
10. Lin YH, Yu CC, Lee SS, Chang YC. Elevated Snail expression in human gingival fibroblasts by cyclosporin A as a possible pathogenesis for gingival overgrowth. *J Formos Med Assoc* 2015;114:1181–6.
11. Tsai CH, Yu CC, Lee SS, Yu HC, Huang FM, Chang YC. Upregulation of Slug expression by cyclosporine A contributes to the pathogenesis of gingival overgrowth. *J Formos Med Assoc* 2016;115:602–8.
12. Chambers I, Colby D, Robertson M, et al. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. *Cell* 2003;113:643–55.
13. Mitsui K, Tokuzawa Y, Itoh H, et al. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. *Cell* 2003;113:631–42.
14. Grant C, Chudakova DA, Itinteang T, et al. Expression of embryonic stem cell markers in keloid-associated lymphoid tissue. *J Clin Pathol* 2016;69:643–6.
15. Ambade A, Satishchandran A, Szabo G. Alcoholic hepatitis accelerates early hepatobiliary cancer by increasing stemness and miR-122-mediated HIF-1α activation. *Sci Rep* 2016;6:21340.
16. Park IH, Zhao R, West JA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. *Nature* 2008;451:141–6.
17. Fischedick G, Wu G, Adachi K, et al. Nanog induces hyperplasia without initiating tumors. *Stem Cell Res* 2014;13:300–15.
18. Sume SS, Kantarci A, Lee A, Hasturk H, Trackman PC. Epithelial to mesenchymal transition in gingival overgrowth. *Am J Pathol* 2010;177:208–18.
19. Mani SA, Guo W, Liao MJ, et al. The epithelial mesenchymal transition generates cells with properties of stem cells. *Cell* 2008;133:704–15.
20. Lu Y, Zhu H, Shan H, et al. Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells. *Cancer Lett* 2013;28(340):113–23.
21. Huang CE, Hu FW, Yu CH, et al. Concurrent expression of Oct4 and Nanog maintains mesenchymal stem-like property of human dental pulp cells. *Int J Mol Sci* 2014;15:18623–39.